TW200630324A - L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide - Google Patents

L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide

Info

Publication number
TW200630324A
TW200630324A TW094139768A TW94139768A TW200630324A TW 200630324 A TW200630324 A TW 200630324A TW 094139768 A TW094139768 A TW 094139768A TW 94139768 A TW94139768 A TW 94139768A TW 200630324 A TW200630324 A TW 200630324A
Authority
TW
Taiwan
Prior art keywords
hydroxy
phenyl
adamantyl
acetamide
hydroxymethyl
Prior art date
Application number
TW094139768A
Other languages
English (en)
Inventor
Kim James
Stefan Colin John Taylor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200630324A publication Critical patent/TW200630324A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW094139768A 2004-11-12 2005-11-11 L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide TW200630324A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0425057A GB0425057D0 (en) 2004-11-12 2004-11-12 L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide

Publications (1)

Publication Number Publication Date
TW200630324A true TW200630324A (en) 2006-09-01

Family

ID=33523659

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094139768A TW200630324A (en) 2004-11-12 2005-11-11 L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide

Country Status (8)

Country Link
AR (1) AR055282A1 (zh)
GB (1) GB0425057D0 (zh)
GT (1) GT200500328A (zh)
NL (1) NL1030405C2 (zh)
PE (1) PE20061131A1 (zh)
TW (1) TW200630324A (zh)
UY (1) UY29207A1 (zh)
WO (1) WO2006051375A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
EP2228368A1 (en) 2009-03-12 2010-09-15 Almirall, S.A. Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
EP2394998A1 (en) 2010-05-31 2011-12-14 Almirall, S.A. 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
HRP20221196T1 (hr) 2017-10-05 2022-12-09 Fulcrum Therapeutics, Inc. Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju liječenja fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222841A1 (en) * 2002-04-25 2003-11-10 Glaxo Group Limited Phenethanolamine derivatives
EP1460064A1 (en) * 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
EP1577291A1 (en) * 2004-03-17 2005-09-21 Pfizer Limited Phenylethanolamine derivatives as beta-2 agonists

Also Published As

Publication number Publication date
UY29207A1 (es) 2006-06-30
GT200500328A (es) 2006-06-02
NL1030405C2 (nl) 2006-12-12
WO2006051375A1 (en) 2006-05-18
PE20061131A1 (es) 2006-10-20
GB0425057D0 (en) 2004-12-15
AR055282A1 (es) 2007-08-15
NL1030405A1 (nl) 2006-05-15

Similar Documents

Publication Publication Date Title
TW200630324A (en) L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide
IL185002A0 (en) Sphingosine 1-phosphate agonists comprising cycloalkanes and 5-membered heterocycles substituted by amino and phenyl groups
CY1106929T1 (el) Κρυσταλλικες μορφες υδροχλωριδιου (-)-(1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλοπροπυλο)-φαινολης
DK1786403T3 (da) Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
ECSP23034537A (es) Formulaciones farmaceuticas
CL2014000492A1 (es) Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras
MA29109B1 (fr) Nouveaux composes de 2-cyano-3(halogeno) alcoxy-benzenesulfonamide pour combattre des organismes nuisibles animaux
HN2009000499A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil} amino)3-fluorofenoxi]-n-metilpiridina-2- carboxamida monohidrato.
EA200870599A1 (ru) Стабильные препараты лаквинимода
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
ECSP10010145A (es) Uso de 3,11b-cis-dihidrotetrabenazina en el tratamiento de la esclerosis múltiple y la mielitis autoinmunitaria
PL1814843T3 (pl) (2R)-enancjomer chlorku DOTAP
BRPI0821696A2 (pt) Compostos 1,2,4-oxadiazol para o tratamento de doenças autoimunes
ITMI20041216A1 (it) Sega curva
MX2011009271A (es) Nuevo compuesto de alfa-(n-sulfonamido)acetamida como inhibidor de la produccion del peptido beta amiloide.
HK1118276A1 (en) Ethanolamine salt of n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4- oxadiazole-2-yl]phenyl)pyridine-3-sulphonamide
EA200970355A1 (ru) Новый кристалл (s)-(+)-2-(2-хлорфенил)-2-гидроксиэтилкарбамата
BRPI0720849A2 (pt) Processos para a preparação de (3r,4r)-n-(4-clorofenil)-1-(2,2-difluoretil)-n'-(2-flúor-4- (2-oxo-1-(2h)-piridinil)fenil]-3,4-pirrolidinadicarboxam ida
DOP2005000231A (es) Sal l-tartrato de n-1-adamantil-2-(3-[(2r)-2-(2r)-2-hidroxi-2-[4-hidroxi-3-(hidroximetil)fenil]etil amino) propil] fenil) acetamida
SG143202A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of periventricular leukomalacia
EA200970368A1 (ru) Новый кристалл (s)-(+)-2-(2-хлорфенил)-2-гидроксиэтилкарбамата
TH80279A (th) เกลือ l-ทาร์เทรตของ n-1-อะดาแมนทิล-2-{3-[(2r)-2-({(2r)-2-ไฮดรอกซี-2-[4-ไฮดรอกซี-3-(ไฮดรอกซีเมธิล)ฟีนิล]เอธิล}อะมิโน)โพรพิล]ฟีนิล}อะเซทาไมด์
CY2004010I2 (el) Phenyl carbamate
TH80279B (th) เกลือ l-ทาร์เทรตของ n-1-อะดาแมนทิล-2-{3-[(2r)-2-({(2r)-2-ไฮดรอกซี-2-[4-ไฮดรอกซี-3-(ไฮดรอกซีเมธิล)ฟีนิล]เอธิล}อะมิโน)โพรพิล]ฟีนิล}อะเซทาไมด์
TH87627B (th) เกลือของ 4-เมทธิล-n-[3-(4-เมทธิล-อิมิดาโซล-1-อิล)-5-ไทรฟลูออโรเมทธิล-เฟนิล]-3-(4-ไพริดิน-3-อิล-ไพริมิดิน-2-อิลอะมิโน)-เบนซาไมด์